Plain-English translation of NCT07321093 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called to see if it can help people with relapsing-remitting multiple sclerosis (a type of MS where symptoms come and go). You would receive the medication by infusion and be compared to people receiving a similar established treatment. The trial will track how well this treatment reduces relapses and how safe it is over about 18 months.
Relapsing-remitting MS can be unpredictable and disabling, with sudden flare-ups that worsen symptoms. Researchers are testing this medication to see if it offers another effective option for patients who need better control of their relapses.
You likely qualify if…
You likely don't qualify if…
You would start with a screening visit to confirm you qualify. If enrolled, you would receive infusions of either the new medication or the comparison treatment over 18 months, with the first two doses at 300 mg and later doses at 600 mg. You would have regular clinic visits for about 96 weeks to monitor your health, have MRI scans, blood tests, and neurological exams, then a brief follow-up period. You would also need to stop any other MS medications and use contraception throughout the study.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Russia
Phase
Large-scale testing
Sponsor
Biocad
Enrollment target
~292 participants
Started
November 2025
Primary completion
December 2028
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Marina Krasnova
Biocad
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.